Last reviewed · How we verify
Dexmedetomidine Injectable Product
Dexmedetomidine is a selective alpha-2 adrenergic receptor agonist that produces sedation, analgesia, and anxiolysis by activating presynaptic and postsynaptic alpha-2 receptors in the central nervous system.
Dexmedetomidine is a selective alpha-2 adrenergic receptor agonist that produces sedation, analgesia, and anxiolysis by activating presynaptic and postsynaptic alpha-2 receptors in the central nervous system. Used for Sedation in intensive care unit patients, Perioperative sedation and analgesia, Procedural sedation.
At a glance
| Generic name | Dexmedetomidine Injectable Product |
|---|---|
| Also known as | Precedex, DEX IV Sedation |
| Sponsor | Eye & ENT Hospital of Fudan University |
| Drug class | Alpha-2 adrenergic receptor agonist |
| Target | Alpha-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Anesthesia and Sedation |
| Phase | Phase 3 |
Mechanism of action
Dexmedetomidine binds with high selectivity to alpha-2 adrenergic receptors, which are distributed throughout the brain and spinal cord. This activation leads to decreased norepinephrine release and reduced neuronal firing, resulting in sedative and analgesic effects. The drug produces a unique sedation profile characterized by maintained airway reflexes and the ability to be aroused, distinguishing it from other sedative agents.
Approved indications
- Sedation in intensive care unit patients
- Perioperative sedation and analgesia
- Procedural sedation
Common side effects
- Hypotension
- Bradycardia
- Hypertension (transient, initial)
- Dry mouth
- Headache
Key clinical trials
- Effect of Lidocaine Infusion Versus Dexmedemidine Infusion on the Neurocognitive Function of Elderly Patients Undergoing Endoscopic Retrograde Cholangiopancreatography(ERCP): a Randomized, Controlled Trial. (NA)
- The Relationship Between Opioid-Free Anesthesia and Postoperative Agitation-Delirium and Quality of Recovery in Pediatric Ear, Nose, and Throat Cases Monitored With Perioperative Bispectral Index
- Continuous Epidural With Dexmedetomidine Adjuvant in Gynecologic Laparotomy (PHASE4)
- Effect of Dexmedetomidine on Brain Homeostasis and Neurocognitive Outcome (PHASE4)
- Suprainguinal Fascia Iliaca Block With vs Without Dexmedetomidine (PHASE4)
- Dexmedotomidine for Acute Pain Control in Patients With Multiple Rib FracturesRandomized Controlled Trial (PHASE4)
- Dexmedetomidine for Invasive Ventilation In the NEOnate (PHASE2, PHASE3)
- Opioid Free and Opioid Based Anesthesia in Elective Lumbar Spine Surgery
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: